Patent ID: 11945787
Assignee: ELA PHARMA LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method for ameliorating, inhibiting, or reducing the incidence of necrotic cell death in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of Formula VI:, or a pharmaceutically acceptable salt thereof,
wherein:
G1 is pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, or piperazinyl, wherein the pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, or piperazinyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, NO2, CN, C1-C6 alkyl, C1-C6 haloalkyl, NH2, OH, OC1-C6 alkyl, C(O)H, C(O)C1-C6 alkyl, C(O)NH2, C(O)OH, and C(O)OC1-C6 alkyl; and
G2 is alkyl, cycloalkyl, heterocyclyl, or aryl, wherein the alkyl, cycloalkyl, heterocyclyl, or aryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, NO2, CN, C1-C6 alkyl, C1-C6 haloalkyl, NH2, OH, OC1-C6 alkyl, C(O)H, C(O)C1-C6 alkyl, C(O)NH2, C(O)OH, and C(O)OC1-C6 alkyl;
wherein the subject suffers from cellular necrosis of a cell selected from the group consisting of a bone cell, a brain cell, a cardiac cell, a cartilage cell, an embryonic cell, an epidermal cell, an epithelial cell, a fibroblast, a gastrointestinal cell, a glial cell, a gonadal cell, a hematopoetic cell, a kidney cell, a liver cell, a lung cell, a lymphocyte, a macrophage, a muscle cell, a neuronal cell, a pancreatic cell, a parenchymal cell, a retinal cell, a spleen cell, and a stem cell.